Amal Thommil, Senior Research Associate at DeciBio, regularly updates us on coverage for minimal residual disease testing. Each updates expands either tumor type (like "breast cancer") or application (like "checkpoint therapy monitoring.") Each time, we see the centrality of coverage determinations at the CMS MolDx program, which sets coverage for both fee for service Medicare and Medicare Advantage.
Here's his most recent chart:
https://www.linkedin.com/feed/update/urn:li:activity:7393750080786395136/
 |
| click to enlarge |